new report turnaround start
concern solosec ramp-up margin contract
play upgrad lupin outperform stock
ignor sharp increas four year two strong
opportun genbrel europ gspiriva inhal us
lupin turn net debt past four year due weak acquisit
gavi solosec low higher wc intens margin
contract due solosec price eros metformin howev
lupin close debt free margin expans
levo albuterol solosec genbrel gspiriva
lower capital-expenditure intens
catalyst genbrel approv eu albuterol
inhal us possibl goa clearanc solosec expect
lupin either reduc resourc share anoth product
increas tp rs rs basi price-to-earnings ep
ex-amortis add rs genbrel gspiriva
ep cut due higher tax
guidanc risk delay albuterol genbrel approv flag
escal mandideep gavi plant introduc ep
figur expect signific pick-up profil lupin
spiriva enbrel rs ignor market
view stock ignor upsid genbrel eu rs
upsid npv gspiriva us rs tp
limit competit larg opportun spiriva inhal
bn drug global lupin file dpi form spiriva
handihal sh bn us sale lupin gener
filer clinic trial on-going us sh market
contract gsk ellipta inhal gain volum share
boehring shift handihal market respimat devic
mdi assum market reduc mn lower
litig key patent composit patent expir
estim lupin launch post
genbrel market eu larg bn
sandoz lupin alreadi approv japan expect
eu approv competit limit follow-on filer
coheru prioritis us file eu expect volum share
thu repres real upsid
enbrel valu drug npv basi
upgrad outperform
estimate pot chg tp
number share mn
chg prev ep
solosec drag reduc lower resourc
product solosec significantli depress profit
posit ramp-up manag reduc expect
mn mn still expect
sub expect lupin either reduc sale rep ramp-
stay weak add anoth brand product share solosec
resourc expect solosec ebitda break-even ep
break-even levothyroxin lupin good start
market share alreadi expect share
sharp increas expect lupin turn net debt past
four year due weak acquisit gavi solosec low
higher wc margin contract due solosec price eros
metformin howev lupin close debt free
margin bottom improv driven ramp-up
levothyroxin solosec albuterol contribut
genbrel gspiriva moder capital-expenditure intens
upgrad outperform increas tp rs tp
base price-to-earnings ep ex-amortis add
upsid npv genbrel gspiriva launch
respect cut ep due higher
 increas tax rate guidanc
risk delay approv genbrel gproair pend
inspect
escal oai flag mandideep somerset gavi facil
disrupt generic-gener scale-up india
dabhasa api plant
figur sum-of-the-part cs target price
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
price rate histori inc biib oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori glaxosmithklin plc gsk
signifi initi assumpt coverag
charl martineau pm univers toronto price rate histori lupin ltd lupn bo
signifi initi assumpt coverag
price rate histori novarti novn
signifi initi assumpt coverag
price rate histori pfe
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european rate base stock total return rel analyst coverag univers consist
compani cover analyst within relev sector outperform repres attract neutral less attract
charl martineau pm univers toronto underperform least attract invest opportun latin american asia stock exclud japan australia rate
base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand stock
expect total return calcul includ roll dividend yield outperform rate assign greater
equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may
rang outperform under-perform rate overlap neutral threshold oper
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
